Matthew B. Klein - Dec 1, 2025 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Avraham S. Alder, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Dec 1, 2025
Transactions value $
-$271,052
Form type
4
Date filed
12/3/2025, 05:20 PM
Previous filing
Aug 5, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klein Matthew B. CHIEF EXECUTIVE OFFICER, Director C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Alder, Attorney-in-Fact 2025-12-03 0001808968

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Award $0 +15.6K +4.63% $0.00 353K Dec 1, 2025 Direct F1
transaction PTCT Common Stock Sale -$271K -3.43K -0.97% $79.07 350K Dec 2, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares of the Issuer's common stock underlying restricted stock units ("RSUs") earned upon the vesting of performance-based restricted stock units ("PSUs") granted in December 2024. On December 1, 2025, the Issuer's board of directors certified the Issuer's achievement of a pre-established milestone set forth in the PSUs, which resulted in the reported RSUs being earned. Each earned RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting. The earned RSUs immediately vested as to 7,812 shares on December 1, 2025 in connection with being earned and are scheduled to vest with respect to the remaining 7,813 shares on December 1, 2026.
F2 Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the RSU grant to satisfy tax withholding obligations in connection with the vesting of the earned RSUs with respect to 7,812 shares on December 1, 2025.